Is It Too Late to Buy Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotech that focuses on treating rare diseases. Its stock has vastly underperformed in the past year after a wild run-up, falling nearly 36% from its July highs.

This is the company that has developed the only pharma-based treatments for cystic fibrosis (CF), a genetic disease that causes persistent lung infections. Vertex had been very successful in tackling the condition and commercializing its drugs. So what went wrong? 

Image source: Getty Images.

Continue reading

Source Fool.com